Skip to content
medxy logo

Medxy AI

  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
Comparative Efficacy and Safety of Prednisone and Methotrexate as First-Line Treatments for Pulmonary Sarcoidosis
Posted innews Oncology Respiratory Specialties

Comparative Efficacy and Safety of Prednisone and Methotrexate as First-Line Treatments for Pulmonary Sarcoidosis

Posted by MedXY By MedXY 08/01/2025
A recent multicenter trial demonstrates methotrexate's noninferiority to prednisone in improving lung function at 24 weeks in pulmonary sarcoidosis, with distinct side-effect profiles informing treatment choices.
Read More
Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation
Posted inClinical Updates Hematology-Oncology news Specialties

Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation

Posted by MedXY By MedXY 08/01/2025
Post-transplant cyclophosphamide plus cyclosporin significantly improves GVHD-free, relapse-free survival compared to standard prophylaxis in matched related donor stem cell transplantation.
Read More
Multidose Ondansetron After Emergency Visits: Reducing Gastroenteritis Severity in Children
Posted inClinical Updates Gastroenterology news Specialties

Multidose Ondansetron After Emergency Visits: Reducing Gastroenteritis Severity in Children

Posted by MedXY By MedXY 08/01/2025
A randomized trial shows that multidose ondansetron after pediatric ED visits for gastroenteritis reduces moderate-to-severe illness, though impact on vomiting duration and healthcare utilization is limited.
Read More
Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort
Posted inClinical Updates Gastroenterology news Specialties

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

Posted by MedXY By MedXY 08/01/2025
A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.
Read More
Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial
Posted inClinical Updates news Oncology Specialties

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

Posted by MedXY By MedXY 07/31/2025
Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.
Read More
Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data
Posted innews Oncology Specialties

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

Posted by MedXY By MedXY 07/31/2025
Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.
Read More
Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial
Posted inClinical Updates news Oncology Specialties

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

Posted by MedXY By MedXY 07/31/2025
Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.
Read More
Mass Ivermectin Administration for Malaria Control: Translational Insights from Recent Cluster-Randomized Trials
Posted inInfectious Diseases Specialties

Mass Ivermectin Administration for Malaria Control: Translational Insights from Recent Cluster-Randomized Trials

Posted by MedXY By MedXY 07/31/2025
Recent cluster-randomized trials in Kenya and Burkina Faso provide mixed but informative evidence on the efficacy and safety of mass ivermectin administration for malaria control, highlighting both its potential and limitations.
Read More
Acute Normovolemic Hemodilution in Cardiac Surgery: No Reduction in Allogeneic Transfusion—Insights from a Multinational Randomized Trial
Posted inCardiology Clinical Updates news Specialties

Acute Normovolemic Hemodilution in Cardiac Surgery: No Reduction in Allogeneic Transfusion—Insights from a Multinational Randomized Trial

Posted by MedXY By MedXY 07/31/2025
A large multinational trial found that acute normovolemic hemodilution (ANH) did not significantly reduce allogeneic red-cell transfusion in adult cardiac surgery patients, with similar safety outcomes compared to usual care.
Read More
Mitochondrial Donation and Preimplantation Genetic Testing: Innovations in Reducing mtDNA Disease Transmission
Posted inClinical Updates Hematology-Oncology Medical News Specialties

Mitochondrial Donation and Preimplantation Genetic Testing: Innovations in Reducing mtDNA Disease Transmission

Posted by MedXY By MedXY 07/31/2025
Mitochondrial donation by pronuclear transfer and preimplantation genetic testing effectively reduce transmission of pathogenic mtDNA variants, offering hope for families at risk of mitochondrial diseases.
Read More
MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial
Posted inClinical Updates Hematology-Oncology Medical News Specialties

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial

Posted by MedXY By MedXY 07/31/2025
MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.
Read More
FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review
Posted inClinical Updates Diabetes & Endocrinology news Specialties

FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review

Posted by MedXY By MedXY 07/31/2025
Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.
Read More
Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity
Posted inClinical Updates news Oncology Specialties

Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity

Posted by MedXY By MedXY 07/31/2025
Dupilumab controls ADC-related skin toxicities more effectively than systemic steroids, reducing cancer treatment discontinuation and improving response rates.
Read More
Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study
Posted inClinical Updates Hematology-Oncology news Specialties

Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study

Posted by MedXY By MedXY 07/31/2025
The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.
Read More
Limited Direct Comparison of Me-Too Oncology Drugs with First-in-Class Agents: Clinical Implications and Regulatory Considerations
Posted innews Oncology Specialties

Limited Direct Comparison of Me-Too Oncology Drugs with First-in-Class Agents: Clinical Implications and Regulatory Considerations

Posted by MedXY By MedXY 07/31/2025
Analysis of FDA approvals from 2009–2020 reveals only 29% of next-in-class oncology drugs underwent head-to-head RCTs against originals, with just 22% showing survival benefits, highlighting a need for incentivized comparative trials.
Read More
Sex-Specific Brain Volume Loss After Traumatic Brain Injury: Greater Impact in Older Women
Posted inNeurology news Specialties

Sex-Specific Brain Volume Loss After Traumatic Brain Injury: Greater Impact in Older Women

Posted by MedXY By MedXY 07/31/2025
A study from the Framingham Heart Study cohort reveals that traumatic brain injury (TBI) is linked to significant brain volume loss in older women but not men, highlighting sex-specific vulnerability to neurodegeneration post-TBI.
Read More
High-Dose and Adjuvanted Flu Vaccines Offer Equivalent Protection for Older US Adults
Posted inCardiology Clinical Updates news Public Health Specialties

High-Dose and Adjuvanted Flu Vaccines Offer Equivalent Protection for Older US Adults

Posted by MedXY By MedXY 07/31/2025
A large US study finds adjuvanted and high-dose quadrivalent influenza vaccines provide comparable protection against lab-confirmed flu in seniors, supporting current immunization guidelines.
Read More
FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease
Posted inClinical Updates news Rheumatology Specialties

FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease

Posted by MedXY By MedXY 07/31/2025
The FDA has approved the first vagus nerve stimulation device for moderate-to-severe rheumatoid arthritis unresponsive to biologic or synthetic DMARDs, offering a novel neuromodulatory approach to disease management.
Read More
Balancing Stroke Prevention and Bleeding Risk: Timing of DOAC Restart After Serious Bleeding in Atrial Fibrillation
Posted inCardiology Clinical Updates news Specialties

Balancing Stroke Prevention and Bleeding Risk: Timing of DOAC Restart After Serious Bleeding in Atrial Fibrillation

Posted by MedXY By MedXY 07/31/2025
Early resumption of DOACs after serious bleeding in AF patients may lower stroke risk but significantly increases recurrent bleeding. Individualized decision-making and further research are recommended.
Read More
Advances in Obesity and Diabetes Management: Highlights from ADA 2025
Posted inDiabetes & Endocrinology news Specialties

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

Posted by MedXY By MedXY 07/31/2025
New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.
Read More

Posts pagination

Previous page 1 … 179 180 181 182 183 … 193 Next page
  • Beyond Blood Sugar: Why Insulin Resistance Drives Vagal Dysfunction in Heart Failure
  • Curbing the Industrial Diet: School-Based Intervention Reduces Adolescent Ultra-Processed Food Intake by 1,000 Kcal Per Day
  • Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
  • Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores
  • Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes
Post You Might Like
Posted inCardiology Diabetes & Endocrinology news
Beyond Blood Sugar: Why Insulin Resistance Drives Vagal Dysfunction in Heart Failure
Posted by MedXY By MedXY 02/04/2026
Posted innews Pediatrics Public Health
Curbing the Industrial Diet: School-Based Intervention Reduces Adolescent Ultra-Processed Food Intake by 1,000 Kcal Per Day
Posted by MedXY By MedXY 02/04/2026
Posted inDiabetes & Endocrinology Internal Medicine news
Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
Posted by MedXY By MedXY 02/04/2026
Posted inGastroenterology Internal Medicine news
Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores
Posted by MedXY By MedXY 02/04/2026
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in